logo inserm ifrb fondateurCC logoUSPN

Publications du Li2P INSERM UMR 1125

Publications du Li2P INSERM UMR 1125

Former publication of present members of Li2P

  • Nucleosome-induced neutrophil activation occurs independently of TLR9 and endosomal acidification: implications for systemic lupus erythematosus. Lindau D, Rönnefarth V, Erbacher A, Rammensee HG, Decker P. Eur J Immunol, 2011, 41:669-81.
  • Antineuronal antibodies in sporadic late-onset cerebellar ataxia. Bürk K, Wick M, Roth G, Decker P, Voltz, R.  J Neurol, 2010, 257:59-62.
  • Neurological symptoms in patients with biopsy proven celiac disease. Bürk K, Farecki ML, Lamprecht G, Roth G, Decker P, Weller M, Rammensee HG, Oertel WHO. Mov Disord, 2009, 24:2358-62.
  • Neutrophils, dendritic cells and chromatin-mediated pathogenesis in systemic lupus erythematosus. Lindau D, Decker P.  Autoimmunity, 2009, 42:254-6.
  • Chromatin modifications, oxidative stress and nucleosome autoantibodies. In: The epigenetics of autoimmune diseases. Erbacher A, Decker P.  2009, 119-34. Editor, Moncef Zouali; Publisher, Wiley Inc., New York.
  • Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA. Kloss M*, Decker P*, Baltz K, Baessler T, Jung G, Rammensee HG, Steinle A, Krusch M, Salih H.  J Immunol, 2008, 181: 6711-19. *The first two authors contributed equally to this work.
  • The PDE4 inhibitor rolipram prevents NF-kappaB binding activity and proinflammatory cytokine release in human chorionic cells. Hervé R, Schmitz T, Evain-Brion D, Cabrol D, Leroy MJ, Méhats C. J Immunol. 2008 Aug 1;181(3):2196-202.
  • Circulating nucleosomes due to a defective clearance of dying cells: consequences in systemic lupus erythematosus. Erbacher A, Rönnefarth V, Decker P.  Autoimmunity, 2007, 40:311-14.
  • Heteroclitic properties of mixed a- and aza-b3-peptides mimicking a supradominant CD4 T cell epitope presented by nucleosome. Dali H, Busnel O, Hoebeke J, Bi L, Decker P, Briand JP, Baudy-Floc’h M, Muller S.  Mol Immunol, 2007, 44:3024-36.
  • TLR2/TLR4-independent neutrophil activation and recruitment upon endocytosis of nucleosomes reveals a new pathway of innate immunity in systemic lupus erythematosus. Rönnefarth V, Erbacher A, Lamkemeyer T, Madlung J, Nordheim A, Rammensee HG, Decker P. J Immunol, 2006, 177:7740-9.
  • Monocyte-derived dendritic cells over-express CD86 in patients with systemic lupus erythematosus. Decker P, Kötter I, Klein R, Berner B, Rammensee HG.  Rheumatology, 2006, 45:1087-95.
  • Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a MyD88-independent pathway: consequences on inflammation. Decker P, Singh-Jasuja H, Haager S, Kötter I, Rammensee HG.  J Immunol, 2005, 174:3326-34.
  • Identification of a naturally processed cyclin D1 T-helper epitope by a novel combination of HLA class II targeting and differential mass spectromotry. Dengjel J*, Decker P*, Schoor O, Altenberend F, Weinschenk T, Rammensee HG, Stevanovic S. Eur J Immunol, 2004, 34:3644-51. *The first two authors contributed equally to this work.
  • Nucleosomes induce lymphocyte necrosis. Decker P, Wolburg H, Rammensee HG.  Eur J Immunol, 2003, 33:1978-87.
  • Detection of nucleosome particles in the sera of patients with SLE using monoclonal antibody 4H7. Williams RC, Malone CC, Meyers C, Decker P, Muller S.  J Rheumatol, 2001, 28:81-94.
  • Inhibition of caspase-3-mediated poly(ADP-ribose) polymerase apoptotic cleavage by human PARP autoantibodies and effect on cells undergoing apoptosis. Decker P, Isenberg DA, Muller S.  J Biol Chem, 2000, 275:9043-6.
  • Molecular and structural properties of three autoimmune IgG monoclonal antibodies to histone H2B. Monestier M, Decker P, Briand JP, Gabriel JL, Muller S.  J Biol Chem, 2000, 275:13558-63.
  • Identification of a minimal T cell epitope recognised by anti-nucleosome Th cells in the C-terminal region of histone H4. Decker P, Le Moal A, Briand JP, Muller S.  J Immunol, 2000, 165:654-62.

Main publications (original papers and review)

  • Deoxyribonuclease 1-mediated Clearance of Circulating Chromatin Prevents from Immune Cell Activation and Pro-inflammatory Cytokine Production, a Phenomenon Amplified by Low Trap1 activity: Consequences for Systemic Lupus Erythematosus. Felux J, Erbacher A, Breckler M, Hervé R, Lemeiter D, Mannherz HG, Napirei M, Rammensee HG, Decker P. Front. Immunol. 2021, In Press.
  • Implication of the deacetylase sirtuin-1 on synovial angiogenesis and persistence of experimental arthritis. Leblond A, Pezet S, Cauvet A, Casas C, Pires Da Silva J, Hervé R, Clavel G, Dumas S, Cohen-Kaminsky S, Bessis N, Semerano L, Lemaire C, Allanore Y, Avouac J.Ann Rheum Dis. 2020 Jul;79(7):891-900. doi: 10.1136/annrheumdis-2020-217377
  • F Santinon, M Batignes, M L Mebrek, J Biton, G Clavel, R Hervé,, D Lemeiter, M Breckler, F Busato, J Tost, M Ziol, MC Boissier, P Decker, ,L Semerano, N Bessis. Involvement of Tumor Necrosis Factor Receptor Type II in FoxP3 Stability and as a Marker of Tregs Cells Specifically Expanded by Anti–Tumor Necrosis Factor Treatments in Rheumatoid Arthritis. Arthritis Rheumatol. 2020 Apr;72(4):576-587. doi: 10.1002/art.41134
  • Origins of rheumatoid arthritis. Boissier MC, Biton J, Semerano L, Decker P, Bessis N. Joint Bone Spine. 2020 Jul;87(4):301-306. doi: 10.1016/j.jbspin.2019.11.009. Epub 2019 Dec 5.
  • Proposal for a combined histo-molecular algorithm to distinguish multiple primary adenocarcinomas from intrapulmonary metastasis in patients with multiple lung tumors. A. Mansuet-Lupo, M. Barritault, M. Alifano, A Janet-Vendroux, M. Zarmaev, J. Biton, Y. Velut, C. Le Hay, I. Cremer2, J-F Régnard, L. Fournel, B. Rance, M. Wislez, P. Laurent-Puig, R. Herbst, D. Damotte, H. Blons.Journal of Thoracic Oncology. 2019 May;14(5):844-856.
  • The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. D. Damotte, S.Warren, J. Arrondeau, P. Boudou-Rouquette, A. Lupo, J. Biton, H. Ouakrim, M. Alifano, C. Gervais, A, Bellesoeur, N. Kramkimel, C. Tlemsani, B. Burroni, A. Duche, F. Letourneur, H. Si, R. Halpin, T. Creasy, R. Herbst, X. Ren, P. Morel, A. Cesano, F. Goldwasser, K. Leroy. Journal of Translational Medicine.  2019 Nov 4;17(1):357.
  • Extracellular Chromatin Triggers Release of Soluble CEACAM8 Upon Activation of Neutrophils. Ribon M, Mussard J, Semerano L, Singer BB, Decker P. Front Immunol. 2019 Jun 14;10:1346.
  • Corneal and scleral involvement in inflammatory rheumatic disease: Rheumatologists and ophthalmologists exchanging views. Clavel G, Gabison E, Semerano L. Joint Bone Spine. 2019 Nov;86(6):699-705. doi: 10.1016/j.jbspin.2019.01.014.
  • Is fat that bad in rheumatoid arthritis? Clavel G, Sigaux J, Semerano L. Joint Bone Spine. 2019 Mar;86(2):129-130. doi: 10.1016/j.jbspin.2018.06.007
  • High prevalence of spondyloarthritis in sarcoidosis patients with chronic back pain.Sigaux J, Semerano L, Nasrallah T, Nunes H, Bouvry D, Valeyre D, Boissier MC, Saidenberg-Kermanac'h N. Semin Arthritis Rheum. 2019 Mar 11. pii: S0049-0172(18)30778-9.
  • Microenvironment tailors nTreg structure and function. Schiavon V, Duchez S, Branchtein M, How-Kit A, Cassius C, Daunay A, Shen Y, Dubanchet S, Colisson R, Vanneaux V, Pruvost A, Roucairol C, Setterblad N, Bouaziz JD, Boissier MC, Semerano L, Graux C, Bensussan A, Burny A, Gallo R, Zagury D, Le Buanec H. Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6298-6307
  • Neutrophil extracellular traps exert both pro- and anti-inflammatory actions in rheumatoid arthritis that are modulated by C1q and LL-37. Ribon M, Seninet S, Mussard J, Sebbag M, Clavel C, Serre G, Boissier MC, Semerano L, Decker P. J Autoimmun. 2019 Mar ;98:122-131.
  • Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment.E. Peranzoni, J. Lemoine, L. Vimeux, V. Feuillet, S. Barrin, C. Kantari, N. Bercovici, M. Guerin, J. Biton, H. Ouakrim, F. Regnier, A. Lupo, M. Alifano, D. Damotte, E.Donnadieu. Proceedings of the National Academy of Sciences. 2018 Apr 24;115(17):E4041-E4050.
  • Impaired tumor-infiltrating T cells in patients with COPD impacts lung cancer response to PD-1 blockade.J. Biton, H. Ouakrim,A. Dechartres, M. Alifano, A. Mansuet-Lupo, H. Si, R. Halpin, T. Creasy, C. Bantsimba-Malanda, J. Arrondeau,F. Goldwasser, P. Boudou-Rouquette, L.Fournel, N. Roche, P-R. Burgel, J. Goc, P. Devi-Marulkar, C. Germain, M-C. Dieu-Nosjean, I. Cremer, R. Herbst, D. Damotte. American Journal of Respiratory and Critical Care Medicine.2018 Oct 1;198(7):928-940.
  • TP53, STK11 and EGFR Mutations Predict Tumor Immune Profile and the Response to anti-PD-1 in Lung Adenocarcinoma. J. Biton, A. Mansuet-Lupo, N. Pécuchet, M. Alifano, H. Ouakrim, J. Arrondeau, P. Boudou-Rouquette, F. Goldwasser, K. Leroy, J. Goc, C. Germain, P. Laurent-Puig, M-C. Dieu-Nosjean, I. Cremer, R. Herbst, H. Blons, D. Damotte.Clinical Cancer Research. 2018 Nov 15;24(22):5710-5723.
  • Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome. V. M. Braud, J. Biton, E. Becht, S. Knockaert, A. Mansuet-Lupo, E. Cosson, D. Damotte, M. Alifano, P. Validire, F. Anjuère, I. Cremer, N. Girard, D.Gossot, A.Seguin-Givelet, M-CDieu-Nosjean & C. Germain. Oncoimmunology. 2018 Dec 8; 5 (12).
  • MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, Kannengiesser C, Ottaviani S, Oka S, Tohma S, Tsuchiya N, Rojas-Serrano J, González-Pérez MI, Mejía M, Buendía-Roldán I, Falfán-Valencia R, Ambrocio-Ortiz E, Manali E, Papiris SA, Karageorgas T, Boumpas D, Antoniou K, van Moorsel CHM, van der Vis J, de Man YA, Grutters JC, Wang Y, Borie R, Wemeau-Stervinou L, Wallaert B, Flipo RM, Nunes H, Valeyre D, Saidenberg-Kermanac'h N, Boissier MC, Marchand-Adam S, Frazier A, Richette P, Allanore Y, Sibilia J, Dromer C, Richez C, Schaeverbeke T, Lioté H, Thabut G, Nathan N, Amselem S, Soubrier M, Cottin V, Clément A, Deane K, Walts AD, Fingerlin T, Fischer A, Ryu JH, Matteson EL, Niewold TB, Assayag D, Gross A, Wolters P, Schwarz MI, Holers M, Solomon JJ, Doyle T, Rosas IO, Blauwendraat C, Nalls MA, Debray MP, Boileau C, Crestani B, Schwartz DA, Dieudé P.N Engl J Med. 2018 Dec 6;379(23):2209-2219. doi: 10.1056/NEJMoa1801562.
  • Tumor Necrosis Factor-Alpha Targeting Can Protect against Arthritis with Low Sensitization to Infection.Belmellat N, Semerano L, Segueni N, Damotte D, Decker P, Ryffel B, Quesniaux V, Boissier MC, Assier E. Front Immunol. 2017 Nov 14;8:1533
  • Salt, inflammatory joint disease, and autoimmunity. Sigaux J, Semerano L, Favre G, Bessis N, Boissier MC. Joint Bone Spine. 2017 Jun 23. pii: S1297-319X(17)30129-X. doi: 10.1016/j.jbspin.2017.06.003.
  • Developments with experimental and investigational drugs for axial spondyloarthritis. Clavel G, Boissier MC, Sigaux J, Semerano L. Expert Opin Investig Drugs. 2017 Jul;26(7):833-842. doi: 10.1080/13543784.2017.1337744
  • Do we need animal models to advance research on inflammatory joint disease? Boissier MC, Bessis N. Joint Bone Spine. 2017 Jul;84(4):381-383
  • Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments. Clavel G, Moulignier A, Semerano L. Joint Bone Spine. 2017 Dec;84(6):671-675. Doi : 10.1016/j.jbspin.2017.03.002. 2017 Mar 18.
  • Arthritis models: usefulness and interpretation. Bessis N, Decker P, Assier E, Semerano L, Boissier MC. Semin Immunopathol. 2017 Jun;39(4):469-486. doi: 10.1007/s00281-017-0622-4.
  • Nutrition and chronic inflammatory rheumatic disease. Semerano L, Julia C, Aitisha O, Boissier MC. Joint Bone Spine. 2017 Oct;84(5):547-552. doi: 10.1016/j.jbspin.2016.10.003.
  • Developments with experimental and investigational drugs for axial spondyloarthritis. Clavel G, Boissier MC, Sigaux J, Semerano L. Expert Opin Investig Drugs. 2017 Jul;26(7):833-842. doi: 10.1080/13543784.2017.1337744.
  • Vaccination Is Suitable for Treating Inflammatory Diseases. Assier E, Bessis N, Zagury JF, Boissier MC. Front Pharmacol. 2017 Jan 31;8:6. doi: 10.3389/fphar.2017.00006.
  • Vitamin D supplementation in patients treated for sarcoidosis: Controversy or consensus? Saidenberg-Kermanac'h N, Valeyre D, Boissier MC. Joint Bone Spine. 2017 Oct;84(5):521-523
  • In Vivo Expansion of Activated Foxp3+ Regulatory T Cells and Establishment of a Type 2 Immune Response upon IL-33 Treatment Protect against Experimental Arthritis. Biton J, Khaleghparast Athari S, Thiolat A, Santinon F, Lemeiter D, Hervé R, Delavallée L, Levescot A, Roga S, Decker P, Girard JP, Herbelin A, Boissier MC, Bessis N. J Immunol. 2016 Sep 1;197(5):1708-19. doi: 10.4049/jimmunol.1502124.
  • Developments with investigational Janus kinase inhibitors for rheumatoid arthritis. Semerano L, Decker P, Clavel G, Boissier MC. Expert Opin Investig Drugs. 2016 Dec;25(12):1355-1359.
  • Personality modulates proportions of CD4+ regulatory and effector T cells in response to socially induced stress in a rodent of wild origin. Rangassamy M, Khaleghparast Athari S, Monclús R, Boissier MC, Bessis N, Rödel HG. Physiol Behav. 2016 Dec 1;167:255-264. doi: 10.1016/j.physbeh.2016.09.016.
  • Time trends in the incidence, prevalence, and severity of rheumatoid arthritis: A systematic literature review. Minichiello E, Semerano L, Boissier MC. Joint Bone Spine. 2016 Dec;83(6):625-630. doi: 10.1016/j.jbspin.2016.07.007.
  • Collagen-induced arthritis and imiquimod-induced psoriasis develop independently of interleukin-33. Athari SK, Poirier E, Biton J, Semerano L, Hervé R, Raffaillac A, Lemeiter D, Herbelin A, Girard JP, Caux F, Boissier MC, Bessis N. Arthritis Res Ther. 2016 Jun 18;18(1):143. doi: 10.1186/s13075-016-1042-x.
  • Novel Immunotherapeutic Avenues for Rheumatoid Arthritis. Semerano L, Minichiello E, Bessis N, Boissier MC. Trends Mol Med. 2016 Mar;22(3):214-29. doi: 10.1016/j.molmed.2016.01.005. Review.
  • Aortic VCAM-1: an early marker of vascular inflammation in collagen-induced arthritis. Denys A, Clavel G, Lemeiter D, Schischmanoff O, Boissier MC, Semerano L. J Cell Mol Med. 2016 May;20(5):855-63. doi: 10.1111/jcmm.12790.
  • Calpains Released by T Lymphocytes Cleave TLR2 To Control IL-17 Expression. Perez J, Dansou B, Hervé R, Levi C, Tamouza H, Vandermeersch S, Demey-Thomas E, Haymann JP, Zafrani L, Klatzmann D, Boissier MC, Letavernier E, Baud L. J Immunol. 2016 Jan 1;196(1):168-81. doi: 10.4049/jimmunol.1500749.
  • Targeting VEGF-A with a vaccine decreases inflammation and joint destruction in experimental arthritis. Semerano L, Duvallet E, Belmellat N, Marival N, Schall N, Monteil M, Grouard-Vogel G, Bernier E, Lecouvey M, Hlawaty H, Muller S, Boissier MC, Assier E. Angiogenesis. 2016 Jan;19(1):39-52. doi: 10.1007/s10456-015-9487-0.
  • Targeting VEGF-A with a vaccine decreases inflammation and joint destruction in experimental arthritisSemerano L, Duvallet E, Belmellat N, Marival N, Schall N, Monteil M, Grouard-Vogel G, Bernier E, Lecouvey M, Hlawaty H, Muller S, Boissier MC, Assier E. . Angiogenesis. 2015 Sep 29.
  • Cachexia and adiposity in rheumatoid arthritis. Relevance for disease management and clinical outcomes.Challal S, Minichiello E, Boissier MC, Semerano L.   Joint Bone Spine. 2015 Jul 13.
  • Metabolomics for rheumatic diseases: has the time come? Semerano L, Roméo PH, Boissier MC.   Ann Rheum Dis. 2015 Jul;74(7):1325-6
  • Therapeutic vaccination with TNF-Kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized, controlled clinical trial. Durez P, Vandepapeliere P, Miranda P, Toncheva A, Berman A, Kehler T, Mociran E, Fautrel B, Mariette X, Dhellin O, Fanget B, Ouary S, Grouard-Vogel G, Boissier MC. PLoS One. 2014 Dec 17;9(12):e113465.
  • Interleukin-6 Receptor Blockade Enhances CD39+ Regulatory T Cell Development in Rheumatoid Arthritis and in Experimental Arthritis. Thiolat A, Semerano L, Pers YM, Biton J, Lemeiter D, Portales P, Quentin J, Jorgensen C, Decker P, Boissier MC, Louis-Plence P, Bessis N. Arthritis Rheumatol. 2014 Feb;66(2):273-83.
  • TLR9 independent interferon α production by neutrophils on NETosis in response to circulating chromatin, a key lupus autoantigen.  Lindau D, Mussard J, Rabsteyn A, Ribon M, Kötter I, Igney A, Adema GJ, Boissier MC, Rammensee HG, Decker P. Ann Rheum Dis. 2013 Sep 7. doi: 10.1136/annrheumdis-2012-203041.
  • Primary blood neutrophils express a functional cell surface Toll-like receptor 9. Lindau D, Mussard J, Wagner BJ, Ribon M,Rönnefarth VM, Quettier M, Jelcic I, Boissier MC, Rammensee HG, Decker P. Eur J Immunol. 2013 Aug;43(8):2101-13.
  • Protection from articular damage by passive or active anti-tumour necrosis factor (TNF)-α immunotherapy in human TNF-α transgenic mice depends on anti-TNF-α antibody levels. Semerano L, Biton J, Delavallée L, Duvallet E, Assier E, Bessis N, Bernier E, Dhellin O, Grouard-Vogel G, Boissier MC   Clin Exp Immunol. 2013 Apr;172(1):54-62. doi: 10.1111/cei.12040
  • Nuclease A (Gbs0661), an extracellular nuclease of Streptococcus agalactiae, attacks the neutrophil extracellular traps and is needed for full virulence. Derré-Bobillot A, Cortes-Perez NG, Yamamoto Y, Kharrat P, Couvé E, Da Cunha V, Decker P, Boissier MC, Escartin F, Cesselin B, Langella P, Bermúdez-Humarán LG, Gaudu P.  Mol Microbiol. 2013 Aug;89(3):518-31.
  • The mouse dendritic cell marker CD11c is down-regulated upon cell activation through Toll-like receptor triggering. Singh-Jasuja H*, Thiolat A*, Ribon M, Boissier MC, Bessis N, Rammensee HG, Decker P.  Immunobiology. 2013 Jan;218(1):28-39.* equal contribution
  • Benchmarking biomedical publications worldwide. Boissier MC. Rheumatology (Oxford). 2013 May 10.
  • Screening for latent tuberculosis in anti-TNF-α candidate patients in a high tuberculosis incidence setting.  Saidenberg-Kermanac'h N, Semerano L, Naccache JM, Brauner M, Falgarone G, Dumont-Fischer D, Guillot X, Valeyre D, Boissier MC. Int J Tuberc Lung Dis. 2012 Oct;16(10):1307-14.
  • TNFα: activator or inhibitor of regulatory T cells?  Biton J, Boissier MC, Bessis N. Joint Bone Spine. 2012 Mar;79(2):119-23.
  • Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. Boissier MC, Semerano L, Challal S, Saidenberg-Kermanac'h N, Falgarone G.  J Autoimmun. 2012 Sep;39(3):222-8.
  • Modulation of anti-tumor necrosis factor alpha (TNF-α) antibody secretion in mice immunized with TNF-αAssier E, Semerano L, Duvallet E, Delavallée L, Bernier E, Laborie M, Grouard-Vogel G, Larcier P, Bessis N, Boissier MC. . Clin Vaccine Immunol. 2012 May;19(5):699-703.
  • Anti-cytokine vaccination: a new biotherapy of autoimmunity? Semerano L, Assier E, Boissier MC. Autoimmun Rev. 2012 Sep;11(11):785.
  • Adrenomedullin, a neuropeptide with immunoregulatory properties induces semi-mature tolerogenic dendritic cells. Rullé S, Ah Kioon MD, Asensio C, Mussard J, Ea HK, Boissier MC, Lioté F, Falgarone G.  Immunology. 2012 Jun;136(2):252-64
  • Active immunization against IL-23p19 improves experimental arthritis.Ratsimandresy RA, Duvallet E, Assier E, Semerano L, Delavallée L, Bessis N, Zagury JF, Boissier MC  Vaccine. 2011 Nov 21;29(50):9329-36
  • Interplay between TNF and regulatory T cells in a TNF-driven murine model of arthritis. Biton J, Semerano L, Delavallée L, Lemeiter D, Laborie M, Grouard-Vogel G, Boissier MC, Bessis N. J Immunol. 2011 Apr 1;186:3899-910.
  • Kinoid of human tumor necrosis factor-alpha for rheumatoid arthritis. Semerano L, Assier E, Delavallée L, Boissier MC.  Expert Opin Biol Ther. 2011 Apr;11(4):545-50. Mar 9.
  • Neutrophils and interferon-a-producing cells: who produces interferon in lupus? Decker P.  Arthritis Res Ther, 2011, 13:118-20.
  • A pivotal role for antigen-presenting cells overexpressing SOCS3 in controlling invariant NKT cell responses during collagen-induced arthritis.  Veenbergen S, Bennink MB, Affandi AJ, Bessis N, Biton J, Arntz OJ, van den Berg WB, van de Loo FA.  Ann Rheum Dis. 2011 Dec;70(12):2167-75.
  • Interleukin-23: A key cytokine in inflammatory diseases. Duvallet E, Semerano L, Assier E, Falgarone G, Boissier MC.  Ann Med. Ann Med. 2011 Nov;43(7):503-11.
  • Cell and cytokine imbalances in rheumatoid synovitis.  Boissier MC. Joint Bone Spine. 2011 ;78:230-4.
  • Interleukin-6: from identification of the cytokine to development of targeted treatments. Assier E, Boissier MC, Dayer JM.  Joint Bone Spine. 2010 ;77:532-6.
  • Blood vessels, a potential therapeutic target in rheumatoid arthritis? Semerano L, Clavel G, Assier E, Denys A, Boissier MC. Joint Bone Spine. 2011;78:118-23.
  • Intra-articular electrotransfer of mouse soluble tumour necrosis factor receptor in a murine model of rheumatoid arthritis. Denys A, Thiolat A, Descamps D, Lemeiter D, Benihoud K, Bessis N, Boissier MC J Gene Med. 2010;12:659-68.
  • Early activation of invariant natural killer T cells in a rheumatoid arthritis model and application to disease treatment. Miellot-Gafsou A, Biton J, Bourgeois E, Herbelin A, Boissier MC, Bessis N. Immunology. 2010 ;130:296-306.
  • Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis. Delavallée L, Semerano L, Assier E, Vogel G, Vuagniaux G, Laborie M, Zagury D, Bessis N, Boissier MC.  Arthritis Res Ther. 2009;11(6):R195. Epub 2009 Dec 23.
  • Regulatory T cells (Treg) in rheumatoid arthritis. Boissier MC, Assier E, Biton J, Denys A, Falgarone G, Bessis N. Joint Bone Spine. 2009;76:10-4.
  • No evidence of major effects in several Toll-like receptor gene polymorphisms in rheumatoid arthritis. Jaen O, Petit-Teixeira E, Kirsten H, Ahnert P, Semerano L, Pierlot C, Cornelis F, Boissier MC, Falgarone G; European Consortium on Rheumatoid Arthritis Families.  Arthritis Res Ther. 2009;11:R5. Epub 2009 Jan 13.
  • Dendritic cells modulated by innate immunity improve collagen-induced arthritis and induce regulatory T cells in vivo Jaen O, Rullé S, Bessis N, Zago A, Boissier MC, Falgarone G. . Immunology. 2009;126:35-44..
  • Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis. Launois R, Payet S, Saidenberg-Kermanac'h N, Francesconi C, França LR, Boissier MC. Joint Bone Spine. 2008;75:688-95.
  • Shifting the imbalance from Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm.  Boissier MC, Assier E, Falgarone G, Bessis N. Joint Bone Spine. 2008;75:373-5.
  • ltrasound and Doppler micro-imaging in a model of rheumatoid arthritis in mice. Clavel G, Marchiol-Fournigault C, Renault G, Boissier MC, Fradelizi D, Bessis N. U Ann Rheum Dis. 2008 ;67:1765-72.
  • Emerging applications of anticytokine vaccines Delavallée L, Assier E, Semerano L, Bessis N, Boissier MC. . Expert Rev Vaccines. 2008;7:1507-17.
  • Vaccination with cytokines in autoimmune diseases. Delavallée L, Assier E, Denys A, Falgarone G, Zagury JF, Muller S, Bessis N, Boissier MC  Ann Med. 2008;40:343-51.
  • arly and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Delavallée L, Le Buanec H, Bessis N, Assier E, Denys A, Bizzini B, Zagury D, Boissier MC. E Ann Rheum Dis. 2008;67:1332-8.
  • synoviocytes infection by AAV is neutralized by human synovial fluid from arthritis patients and depends on AAV serotype. Boissier M-C, Lemeiter D., Valvason C Clavel G, Laroche L. , Begue T., and Bessis N. SHum Gene Ther, 2007 , 18 : 525-35.
  • Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clavel C, Bessis N, Fardellone P, Othmane M, Menard JF, Pouplin S, Boumier P, Vittecoq O, Le Loêt X, Boissier MC.  Clin Immunol,2007, 124: 158-64.
  • Kinoid vaccination-induced neutralizing antibodies to TNFα protects mice from autologous TNFα driven chronic and acute inflammation Le Buanec H*, Delavallée L*, Bessis N,  Paturance S, Bizzini B, Gallo R,  Zagury D, Boissier MC. TNFα  (* same ctd). Proc Natl Acad Sci, 2006,103:19442-7
  • Improvement of collagen-induced arthritis by active immunization against murine IL-1 peptides designed by molecular modelling. Bertin-Maghit SM, Capini CJ , Bessis N, Chomilier J, Muller S, Abbas A, Regulier EG, Rappaport J, Therwath A, Zagury JF*, Boissier MC*.  Vaccine 2005, 23:4228-35 (* same cont.)
  • Practices for Managing a Flare of Long-Standing Rheumatoid Arthritis: Survey among French Rheumatologists Maravic M, Bergé C, Daurès JP, Boissier MC , Clin Exp Immunol, 2005,23:36-42
  • TNF-a antibodies and osteoprotegerin decrease systemic bonne loss-associated with inflammation through distinct mechanisms in collagen-induced arthritis. Saidenberg-Kermanac’h N, Corrado A, Lemeiter D, de Vernejoul MC, Boissier MC, Cohen-Solal M.  Bone, 2004, 35:1200-7
  • Gene therapy of collagen-induced arthritis by electrotransfer of human tumor necrosis factor-alpha soluble receptor I variants. Bessis N*, Bloquel N*, Boissier MC, Scherman D, Bigey P. Hum Gene Ther 2004 ; 15 : 189-201
  • Effect of Synovial Fluid on Adeno-Associated Virus-Mediated Gene Transfer to Chondrocytes Cottard V, Valvasson C, Falgarone G, Lutomski D, Boissier MC, Bessis N  J Clin Immunol, 2004, 24 : 162-9
  • IgG reactivity with a 100 kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited abd diffuse systemic sclerosis patients. Garcia de la Pena-Lefebvre P, Chanseaud Y, Tamby MC, Reinbolt J, Batteux F, Allanore Y, Kahan A, Meyer O, Benveniste O, Boyer O, Guillevin L, Boissier MC, Mouthon L.  Clin Immunol 2004, 11:241-51
  • Survey of Practices Regarding Management of Early Typical Rheumatoid Arthritis by Rheumatologists in France. Maravic M, Bergé C, Daurès JP, Boissier MC , Clin Exp Rheumatol, 2004, 22:319-27
  • Osteoprotegerin and interleukin-4 cellular gene therapy decrease bone resorption-associated inflammation in collagen-induced arthritis Saidenberg-Kermanac’h N, Bessis N, Lemeiter D, de Vernejoul MC, Boissier MC, Cohen-Solal M. . J Clin Immunol, 2004, 24 :370-8
  • Efficacy of interleukin-10 gene electrotransfer into skelettal muscle in mice with collagen-induced arthritis. Saidenberg-Kermanac’h N, Bessis N, Deleuze V, Blocquel C, Bureau M, Scherman D,Boissier MC.  J Gene Med, 2003, 5; 164-71
  • Syngeneic fibroblasts engineered to secrete interleukin-4 as vectors for antiinflammatory gene therapy in collagen-induced arthritis. Bessis N, Cottard V, Saidenberg-Kermanac’h N, Lemeiter D, Fournier C, Boissier MC.  J Gene Med, 2002, 4 :300-7
  • Osteoprotegerin and inflammation. Saidenberg-Kermanac’h N, Bessis N, Cohen-Solal M, de Vernejoul M, Boissier MC.  Eur Cytokine Netw, 2002, 13 :144-53
  • Gene therapy for rheumatoid arthritis. Bessis N, Doucet C, Cottard V, Douar AM, Firat H, Jorgensen C, Mezzina M, Boissier MC  J Gene Med, 2002 ;4 :581-91
  • ardiac manifestations of rheumatoid arthritis : a case control transoesophageal echocardiography study in 30 patients. Guedes C, Bianchi-Fior P, Cormier B, Barthelemy B, Rat AC, Boissier MC. C Arthritis Rheum , 2001, 45:129-35.
  • Collagen II-pulsed antigen-presenting cells engineered to secrete IL-4 down regulate collagen-induced arthritis. Guéry L, Chiocchia G, Batteux F, Boissier MC C, Fournier C.  Gene Ther, 2001, 8 : 1855,62
  • Expression of fas ligand improves the therapeutic effect if IL-4 in collagen-induced arthritis Guéry L, Batteux F, Bessis N, Bréban M, Boissier MC, Fournier C, Chiocchia G. . Eur J Immunol, 2000;30:308-15
  • The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis. Bessis N, Guéry L, Mantovani A, Vecchi A, Sims J, Fradelizi D, Boissier MC.  Eur J Immunol,2000;30:867-75
  • Adeno-associated virus mediated delivery of IL-4 prevents collagen-induced arthritis. Cottard V, Mulleman Bouillé P, Mezzina M, Boissier MC, Bessis N.  Gene Ther, 2000; 7: 1930-9
  • Nucleosome-induced neutrophil activation occurs independently of TLR9 and endosomal acidification: implications for systemic lupus erythematosus. Lindau D, Rönnefarth V, Erbacher A, Rammensee HG, Decker P. Eur J Immunol, 2011, 41:669-81.
  • Antineuronal antibodies in sporadic late-onset cerebellar ataxia. Bürk K, Wick M, Roth G, Decker P, Voltz, R.  J Neurol, 2010, 257:59-62.
  • Neurological symptoms in patients with biopsy proven celiac disease. Bürk K, Farecki ML, Lamprecht G, Roth G, Decker P, Weller M, Rammensee HG, Oertel WHO. Mov Disord, 2009, 24:2358-62.
  • Neutrophils, dendritic cells and chromatin-mediated pathogenesis in systemic lupus erythematosus. Lindau D, Decker P.  Autoimmunity, 2009, 42:254-6.
  • Chromatin modifications, oxidative stress and nucleosome autoantibodies. In: The epigenetics of autoimmune diseases. Erbacher A, Decker P.  2009, 119-34. Editor, Moncef Zouali; Publisher, Wiley Inc., New York.
  • Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA. Kloss M*, Decker P*, Baltz K, Baessler T, Jung G, Rammensee HG, Steinle A, Krusch M, Salih H.  J Immunol, 2008, 181: 6711-19. *The first two authors contributed equally to this work.
  • The PDE4 inhibitor rolipram prevents NF-kappaB binding activity and proinflammatory cytokine release in human chorionic cells. Hervé R, Schmitz T, Evain-Brion D, Cabrol D, Leroy MJ, Méhats C. J Immunol. 2008 Aug 1;181(3):2196-202.
  • Circulating nucleosomes due to a defective clearance of dying cells: consequences in systemic lupus erythematosus. Erbacher A, Rönnefarth V, Decker P.  Autoimmunity, 2007, 40:311-14.
  • Heteroclitic properties of mixed a- and aza-b3-peptides mimicking a supradominant CD4 T cell epitope presented by nucleosome. Dali H, Busnel O, Hoebeke J, Bi L, Decker P, Briand JP, Baudy-Floc’h M, Muller S.  Mol Immunol, 2007, 44:3024-36.
  • TLR2/TLR4-independent neutrophil activation and recruitment upon endocytosis of nucleosomes reveals a new pathway of innate immunity in systemic lupus erythematosus. Rönnefarth V, Erbacher A, Lamkemeyer T, Madlung J, Nordheim A, Rammensee HG, Decker P. J Immunol, 2006, 177:7740-9.
  • Monocyte-derived dendritic cells over-express CD86 in patients with systemic lupus erythematosus. Decker P, Kötter I, Klein R, Berner B, Rammensee HG.  Rheumatology, 2006, 45:1087-95.
  • Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a MyD88-independent pathway: consequences on inflammation. Decker P, Singh-Jasuja H, Haager S, Kötter I, Rammensee HG.  J Immunol, 2005, 174:3326-34.
  • Dengjel J*, Decker P*, Schoor O, Altenberend F, Weinschenk T, Rammensee HG, Stevanovic S. Identification of a naturally processed cyclin D1 T-helper epitope by a novel combination of HLA class II targeting and differential mass spectromotry. Eur J Immunol, 2004, 34:3644-51. *The first two authors contributed equally to this work.
  • Nucleosomes induce lymphocyte necrosis. Decker P, Wolburg H, Rammensee HG.  Eur J Immunol, 2003, 33:1978-87.
  • Detection of nucleosome particles in the sera of patients with SLE using monoclonal antibody 4H7. Williams RC, Malone CC, Meyers C, Decker P, Muller S.  J Rheumatol, 2001, 28:81-94.
  • Inhibition of caspase-3-mediated poly(ADP-ribose) polymerase apoptotic cleavage by human PARP autoantibodies and effect on cells undergoing apoptosis. Decker P, Isenberg DA, Muller S.  J Biol Chem, 2000, 275:9043-6.
  • Molecular and structural properties of three autoimmune IgG monoclonal antibodies to histone H2B. Monestier M, Decker P, Briand JP, Gabriel JL, Muller S.  J Biol Chem, 2000, 275:13558-63.
  • Identification of a minimal T cell epitope recognised by anti-nucleosome Th cells in the C-terminal region of histone H4. Decker P, Le Moal A, Briand JP, Muller S.  J Immunol, 2000, 165:654-62.

Main publications (original papers and review)

USPN Campus de Bobigny

tour illustration bobigny

web li2p V3

-->